CN1042699C - Female hormone plaster - Google Patents
Female hormone plaster Download PDFInfo
- Publication number
- CN1042699C CN1042699C CN91105330A CN91105330A CN1042699C CN 1042699 C CN1042699 C CN 1042699C CN 91105330 A CN91105330 A CN 91105330A CN 91105330 A CN91105330 A CN 91105330A CN 1042699 C CN1042699 C CN 1042699C
- Authority
- CN
- China
- Prior art keywords
- plaster
- medicine
- female hormone
- stype
- estrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The present invention relates to a novel design of a plaster containing female hormones. The plaster (disclosed in the specification) is composed of six layers of different materials. A medicine with female hormones is dissolved in a proper solvent, injected in a medicinal cloth layer C and then covered by a thin controlled release membrane D. The transdermal absorption plaster prepared by the technique has the advantages of long-acting function of using medicine, convenient use and stable medicinal effect, has the same pharmacological as the subcutaneous injection, has no pain sense and is a latest scientific and technical product for treating various physiological barriers of climacteric women.
Description
The absorption of all medicines is through after subcutaneous injection or the intravenous drip, enters systemic blood blood circulation person, is referred to as the percutaneous medicament dosage form.Because the continuous progressive innovation of science and technology, new percutaneous absorption type can utilize medicinal infiltration own and diffusion principle, medicine is made paster after, directly be covered in skin surface and reach the pharmacological effect that is equal to subcutaneous injection.Use the great advantage of this kind science and technology paster to be, but except user was avoided the misery of skin and flesh, its drug effect also can continue a couple of days reposefully.
Since in 1982, the percutaneous absorption adhesive patch of this type is finished via the pharmaceutical factory exploitation of U.S. number man and is released the person of going on the market prevents the various physiological function obstacles that clonidine (CLONI DI NE) that carsick scopolamine (3) resisting hypertension peculiar to vessel is used and (4) treatment women arrived to produce because of climacteric in respect of the nitroglycerin (2) of (1) treatment angina pectoris estrogen smoothly.
Contained according to United States Patent (USP) No. 4336243 (June 22 nineteen eighty-two), the design of nitroglycerin percutaneous absorption adhesive patch is the controlled release system that adopts silicone rubber to disengage as medicine.This jelly is through after the special chemical treatment, could form numerous little envelope every asking that (MI CROSEALEDCOMP ARTMENTS) nitroglycerin promptly is to be stored in these small compartments (COMP ARTENTS), discharges slowly with certain speed.
Contained according to United States Patent (USP) No. 4379454 (April 12 nineteen eighty-three), the design of female hormone plaster is to adopt the rubbery polymeric substrate of HPC (KLUCEL) as carrier, and this colloid contains a large amount of ethanol as the absorption enhancement agent in addition.The controlled release system that the thin film that this paster adopts ethyl vinyl acetate and polyisobutylene to make disengages as medicine.
According to No. the 4615699th, United States Patent (USP) (on October 7th, 1986), No. 4661105 (on April 28th, 1987) and No. 4704119 (on November 3rd, 1987) is contained, and nitroglycerin percutaneous absorption adhesive patch also can adopt with No. 4379454 identical design of aforementioned patent and make.
Contained according to United States Patent (USP) No. 4588580 (on May 13rd, 1986), the design of narcotics fentanyl (FENTANYL) percutaneous absorption adhesive patch is to adopt the water solublity colloid as carrier, the controlled release system that polyisobutylene and siloxanes disengage as medicine and making.
Contained according to United States Patent (USP) No. 4690683 (on JIUYUE 1st, 1987), the design of the percutaneous absorption adhesive patch of antihypertensive verapamil (VERAPAMIL) is to adopt to disengage the controlled release principle with No. 4336243 identical medicine of aforementioned patent and make.
Contained according to United States Patent (USP) No. 4788064 (on November 29th, 1988), the percutaneous absorption adhesive patch design of anti-asthma medicine procaterol (PROCATEROL) is to adopt to disengage the controlled release principle with No. 4379454 identical medicine of aforementioned patent and make.
Contained according to United States Patent (USP) No. 4789547 (on December 6th, 1988), the percutaneous absorption adhesive patch design of this anti-asthma medicine also can adopt cross-linked carboxymethyl cellulose as carrier, and linoleic acid and propylene glycol are made as solvent.
The design of female hormone plaster of the present invention is adopted the controlled release system different with above-mentioned each patent and is made.This percutaneous absorption adhesive patch is to adopt a kind of non-interweaving property stype to inhale work agent (or claiming carrier) as medicine; with organic solvents such as the propylene glycol ester of two sad/two capric acid and ethanol as solvent; estrogen injects medicine and inhales work stype C (the about 3.6cm of diameter) after this dissolution with solvents; and covering last layer porous polyethylene film D (the about 4.4cm of diameter); be sealed in air impermeability aluminum film B with these two layers and go up (the about 4.9cm of diameter); then the stype of this good seal is sandwiched in one deck and contains the thin slice A (the about 7.5cm of diameter) of sticking work agent and one deck and contain peeling off of siloxanes and encircle between E and one deck protectiveness aluminium foil F (the about 7.5cm of diameter), sealed at last and finish.Paster of the present invention is made up of above-mentioned six layers of different materials as shown in drawings.
Comprise estrogen 0.1-10 weight % in the female hormone plaster that the present invention relates to, and the mixed solvent 90.0-99.9 weight % of the propylene glycol ester of two sad/two capric acid and ethanol.Wherein, two is sad/and the propylene glycol ester of two capric acid and the volume ratio of ethanol are 10: 90 to 90: 10.Alcohol concentration is 75%.For releasing the control system, every sq contains 0.1-10 milligram estrogen to paster of the present invention with porous polyethylene film.
The rate of disengaging contained in No. the 4379454th, the rate of disengaging that paster the experiment proved that its estrogen and the aforementioned patent data is identical.That is to be medicine that the 45-50 microgram arranged in per 24 hours approximately discharged by 10 square centimeters stype area and enter skin, this paster is through being applied to the phenomenon that did not peel off after 72 hours on the human body skin surface again, and skin there is no irritated or any irritating phenomenon to this paster and produces, the use that proves this invention is not only convenient, effective and safety.The area of this paster must be looked the medicine expense and be adjusted, and the medicine content of average 20 sq is 8 milligrams, and the medicine content of average 10 sq is 4 milligrams, and the rest may be inferred.The drawing that accompanying drawing 1 is is example with 10 square centimeters of stype areas.
Claims (4)
1. method for preparing female hormone plaster; this method may further comprise the steps: adopt a kind of non-interweaving property stype as the medicine sorbent; with the propylene glycol ester of two sad/two capric acid and ethanol as mixed solvent; medicine sorption stype is injected in estrogen dissolving back; and covering last layer porous polyethylene film; these two layers are sealed on the air impermeability aluminum film; then the stype of this good seal is sandwiched in thin slice and one deck that one deck contains sticker and contains peeling off between ring and one deck protectiveness aluminium foil of siloxanes, sealed at last.
2. the method for preparing female hormone plaster according to claim 1, wherein the content of estrogen is 0.1-10 weight %, the content of the two sad/propylene glycol esters of two capric acid and the mixed solvent of ethanol is 90.0-99.9 weight %.
3. the method for preparing female hormone plaster according to claim 1, two is sad in the wherein said mixed solvent/and the malonate of two capric acid and the volume ratio of ethanol are 10: 90 to 90: 10.
4. according to each described method for preparing female hormone plaster among the claim 1-3, wherein said paster contains 0.1-10 milligram estrogen for every square centimeter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN91105330A CN1042699C (en) | 1991-07-10 | 1991-07-10 | Female hormone plaster |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN91105330A CN1042699C (en) | 1991-07-10 | 1991-07-10 | Female hormone plaster |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1068265A CN1068265A (en) | 1993-01-27 |
| CN1042699C true CN1042699C (en) | 1999-03-31 |
Family
ID=4907081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN91105330A Expired - Fee Related CN1042699C (en) | 1991-07-10 | 1991-07-10 | Female hormone plaster |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1042699C (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321252A (en) * | 1979-08-14 | 1982-03-23 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing ester derivatives of estradiol |
| US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
-
1991
- 1991-07-10 CN CN91105330A patent/CN1042699C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321252A (en) * | 1979-08-14 | 1982-03-23 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing ester derivatives of estradiol |
| US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1068265A (en) | 1993-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1164749A (en) | Bandage for administering beneficial drug | |
| US4849226A (en) | Method for increasing oxygen supply by administering vasodilator | |
| AU695170B2 (en) | Transdermal delivery system with adhesive overlay and peel seal disc | |
| KR930001082B1 (en) | Device for administering an active agent to the skin or mucosa | |
| US5830505A (en) | Active ingredient patch | |
| US4834979A (en) | Medical bandage for administering beneficial drug | |
| CN102099020B (en) | Stabilized transdermal drug delivery system | |
| JP2700362B2 (en) | Plaster with a high content of active substance, or active substance and adjuvants | |
| US4661105A (en) | Medical bandage for administering vasodilator drug | |
| JP3523259B2 (en) | Plasters containing volatile active substances that can be produced without solvents | |
| US4814173A (en) | Silicone elastomer transdermal matrix system | |
| JPH02500741A (en) | Transdermal administration unit and method of administration for narcotic analgesics and antagonists | |
| KR20010036685A (en) | Transdermal fentanyl delivery matrix system | |
| JPH09509960A (en) | Transdermal delivery device for drug-containing adhesive complex | |
| WO2009119672A1 (en) | COMPOSITION FOR STABILIZING β-BLOCKER, AND TRANSDERMALLY ABSORBABLE PREPARATION COMPRISING THE COMPOSITION | |
| NL8201034A (en) | Bandage for administration of a holy drug. | |
| US4956181A (en) | Nitrate therapy for angina pectoris | |
| JPS6049601B2 (en) | treatment device | |
| US4954344A (en) | Method for treating nocturnal angina | |
| EP0301589A2 (en) | Procaterol transdermal delivery system | |
| US4812313A (en) | Method for lessening the incidence of anginal attacks | |
| EP0290262A2 (en) | Improved nitrate therapy for angina pectoris | |
| CN1042699C (en) | Female hormone plaster | |
| US5869089A (en) | Manufacturing method of programmable transdermal therapeutic system | |
| JPH02149514A (en) | Material for medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
| OR01 | Other related matters | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |